Inspections, Compliance, Enforcement, and Criminal Investigations
Holy Cross Medical Group 25-Jun-01
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration
555 Winderley Pl., Ste. 200
Maitland, FL 32751
VIA FEDERAL EXPRESS
June 25, 2001
FACILITY ID # 223462
Anthony Lambuta, Director
Holy Cross Medical Group
1309 South Federal Highway
Fort Lauderdale, Florida 33316
Dear Mr. Lambuta:
We are writing to you because on May 17, 2001, your facility was inspected by a representative of the State of Florida, acting on behalf of the Food and Drug Administration (FDA). This inspection revealed a serious regulatory problem involving the mammography at your facility.
Under a United States Federal law, the Mammography Quality Standards Act of 1992, your facility must meet specific requirements for mammography. These requirements help protect the health of women by assuring that a facility can perform quality mammography. The inspection revealed the following level 2 and/or REPEAT Level 2 findings at your facility:
Level 2 ? REPEAT: Your facility did not specify adequate procedures to be followed for infection control or did not follow them when required.
Level 2- REPEAT: Your facility has not specified adequate written procedures for collecting and resolving consumer complaints or did not follow them when required.
A finding is considered to be a repeat finding if the same type of violation was cited during a previous inspection, whether or not the finding is associated with the same piece of equipment (x-ray unit, processor, darkroom) or the same personnel in any given category.
We are including your response to the inspection dated May 22, 2000 referencing the previously cited violations and your commitment to comply with the Quality Standards for Mammography.
The specific problems noted above appeared on your MQSA Facility Inspection Report, which was issued to your facility at the close of the inspection. Because these conditions may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility, they represent a serious violation of the law which may result in FDA taking regulatory action without further notice to you. These actions include, but are not limited to, placing your facility under a Directed Plan of Correction, charging your facility for the cost of on-site monitoring, assessing civil money penalties up to $10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, the Standards, suspension or revocation of your facility?s FDA certificate, or obtaining a court injunction against further mammography.
It is necessary for you to act on this matter immediately. Please explain to this office in writing within fifteen (15) working days from the date you received this letter:
- the specific steps you have taken to correct all of the violations noted in this letter;
- each step your facility is taking to prevent the recurrence of similar violations;
- equipment settings (including technique factors), raw test data, and calculated final results, where appropriate; and
- sample records that demonstrate proper record keeping procedures, if the findings relate to quality control or other records (Note: Patient names or identification should be deleted from any copies submitted).*
Please submit your response to Timothy J. Couzins, Compliance Officer, U.S. Food & Drug Administration, 555 Winderley Place, Suite 200, Maitland, Florida 32751, (407) 475-4728.
Finally, you should understand that there are many FDA requirements pertaining to mammography. This letter pertains only to findings of your inspection and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA?s requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838-7715) or through the Internet at http://www.fda.gov.
If you have more specific questions about mammography facility requirements, or about the content of this letter, please feel free to contact D. Janneth Caycedo, Consumer Safety Officer, Food and Drug Administration, 1499 W. Palmetto Park Road, Ste. 110, Boca Raton, Florida 33486 or you may reach her at (561) 338-5236, ext 23.
Kendall W. Hester for Emma R. Singleton
Director, Florida District